MicroRNA expression profiles in the management of papillary thyroid cancer

Oncologist

Volumn 19, Issue 11, 2014, Pages 1141-1147

  Lee, James C ^a,b,c,d   Gundara, Justin S ^c,d   Glover, Anthony ^c,d   Serpell, Jonathan ^a,b   Sidhu, Stan B ^c,d,e  

^a MONASH UNIVERSITY   (Australia)

^b ALFRED HOSPITAL   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d UNIVERSITY OF SYDNEY   (Australia)

^e ROYAL NORTH SHORE HOSPITAL   (Australia)

Author keywords

Biological markers; miRNAs; Papillary carcinoma; Prognosis; Translational medical research

Indexed keywords

ARGONAUTE PROTEIN; B RAF KINASE; CARCINOEMBRYONIC ANTIGEN RELATED CELL ADHESION MOLECULE 1; CYCLIN D1; MICRORNA; MICRORNA 130B; MICRORNA 146B; MICRORNA 151; MICRORNA 155; MICRORNA 181B; MICRORNA 197; MICRORNA 21; MICRORNA 221; MICRORNA 222; MICRORNA 328; OSTEOPONTIN; PROTEIN P21; PROTEIN P27; THYROGLOBULIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; UVOMORULIN; MESSENGER RNA; TUMOR MARKER;

ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CELL INVASION; CELL MATURATION; CELL MIGRATION; DIAGNOSTIC ACCURACY; DOWN REGULATION; GENE EXPRESSION; GENE MUTATION; GENE OVEREXPRESSION; GENETIC HETEROGENEITY; HUMAN; MICROARRAY ANALYSIS; NORTHERN BLOTTING; PAPILLARY THYROID CANCER; REGULATORY MECHANISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SYSTEMATIC REVIEW (TOPIC); THYROID CANCER; UPREGULATION; CARCINOMA; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; PATHOLOGY; PROGNOSIS; THYROID NEOPLASMS; TRANSLATIONAL RESEARCH;

BIOMARKERS, TUMOR; CARCINOMA; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICRORNAS; PROGNOSIS; RNA, MESSENGER; THYROID NEOPLASMS; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84908505278     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2014-0135     Document Type: Article

References (52)

1. Tracy E, Baker D, Chen W et al. Cancer in New South Wales: Incidence, Mortality and Prevalence 2005. Sydney, New South Wales, Australia: Cancer Institute NSW, 2007.
2. Leenhardt L, Grosclaude P, Cherie-Challine L Increased incidence of thyroid carcinoma in France: A true epidemic or thyroid nodule management effects? Report from the French Thyroid Cancer Committee. Thyroid 2004;14:1056-1060.
3. Enewold L, Zhu K, Ron E et al. Rising thyroid cancer incidence in the United States bydemographic and tumor characteristics, 1980-2005. Cancer Epidemiol Biomarkers Prev 2009;18:784-791.
4. Liu S, Semenciw R, Ugnat AM et al. Increasing thyroid cancer incidence in Canada, 1970-1996: Time trends and age-period-cohort effects. Br J Cancer 2001;85:1335-1339.
5. Cooper DS, Doherty GM, Haugen BR et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009;19:1167-1214.
6. Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 1993;75: 843-854.
7. Wightman B, Ha I, Ruvkun G. Posttranscriptional regulation of the heterochronic gene lin-14 by lin-4 mediates temporal pattern formation in C. elegans. Cell 1993;75:855-862.
8. Reinhart BJ, Slack FJ, Basson M et al. The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans. Nature 2000;403:901-906.
9. Slack FJ, Basson M, Liu Z et al. The lin-41 RBCC gene acts in the C. elegans heterochronic pathway between the let-7 regulatory RNA and the LIN-29 transcription factor. Mol Cell 2000;5:659-669.
10. Pasquinelli AE, Reinhart BJ, Slack F et al. Conservation of the sequence and temporal expression of let-7 heterochronic regulatory RNA. Nature 2000;408:86-89.
11. Lee RC, Ambros V. An extensive class of small RNAs in Caenorhabditis elegans. Science 2001;294: 862-864.
12. Winter J, Jung S, Keller S et al. Many roads to maturity: MicroRNA biogenesis pathways and their regulation. Nat Cell Biol 2009;11:228-234.
13. Lund E, Guttinger S, Calado A et al. Nuclearexport of microRNA precursors. Science 2004;303:95-98.
14. Hussain MUI. Micro-RNAs(miRNAs): Genomic organisation, biogenesis and mode of action. Cell Tissue Res 2012;349:405-413.
15. Curtis HJ, Sibley CR, Wood MJA. Mirtrons, an emerging class of atypical miRNA. Wiley Interdiscip Rev RNA 2012;3:617-632.
16. Meltzer PS. Cancer genomics: Small RNAs with big impacts. Nature 2005;435:745-746.
17. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer 2006;6:857-866.
18. Calin GA, Croce CM. MicroRNA-cancer connection: The beginning of a new tale. Cancer Res 2006;66:7390-7394.
19. Rosenfeld N, Aharonov R, Meiri E et al. Micro-RNAs accurately identify cancer tissue origin. Nat Biotechnol 2008;26:462-469.
20. Liu A, Tetzlaff MT, Vanbelle P et al. MicroRNA expression profiling outperforms mRNA expression profiling in formalin-fixed paraffin-embedded tissues. Int J Clin Exp Pathol 2009;2:519-527.
21. Liu A, Xu X. MicroRNA isolation from formalin-fixed, paraffin-embedded tissues. Methods Mol Biol 2011;724:259-267.
22. Xi Y, Nakajima G, Gavin E et al. Systematic analysis of microRNA expression of RNA extracted from fresh frozen and formalin-fixed paraffin-embedded samples. RNA 2007;13:1668-1674.
23. He H, Jazdzewski K, Li W et al. The role of microRNA genes in papillary thyroid carcinoma. Proc Natl Acad Sci USA 2005;102:19075-19080.
24. Visone R, Russo L, Pallante P et al. MicroRNAs (miR)-221 and miR-222, both overexpressed in human thyroid papillary carcinomas, regulate p27Kip1 protein levels and cell cycle. Endocr Relat Cancer 2007;14:791-798.
25. Tetzlaff MT, Liu A, Xu X et al. Differential expression of miRNAs in papillarythyroid carcinoma compared to multinodular goiter using formalin fixed paraffin embedded tissues. Endocr Pathol 2007;18:163-173.
26. Pallante P, Visone R, Ferracin M et al. MicroRNA deregulation in human thyroid papillary carcinomas. Endocr Relat Cancer 2006;13:497-508.
27. Nikiforova MN, Tseng GC, Steward D et al. MicroRNA expression profiling of thyroid tumors: Biological significance and diagnostic utility. J Clin Endocrinol Metab 2008;93:1600-1608.
28. Kitano M, Rahbari R, Patterson EE et al. Expression profiling of difficult-to-diagnose thyroid histologic subtypes shows distinct expression profiles and identify candidate diagnostic microRNAs. Ann Surg Oncol 2011;18:3443-3452.
29. Vriens MR, Weng J, Suh I et al. MicroRNA expression profiling is a potential diagnostic tool for thyroid cancer. Cancer 2012;118:3426-3432.
30. Yip L, Kelly L, Shuai Y et al. MicroRNA signature distinguishes the degree of aggressiveness of papillary thyroid carcinoma. Ann Surg Oncol 2011;18: 2035-2041.
31. Huang Y, Liao D, Pan L et al. Expressions of miRNAs in papillary thyroid carcinoma and their associations with the BRAF (V600E) mutation. Eur J Endocrinol 2013;168:675-681.
32. Cibas ES, Ali SZ. The Bethesda System for Reporting Thyroid Cytopathology. Thyroid 2009;19: 1159-1165.
33. Keutgen XM, Filicori F, Crowley MJ et al. A panel of four miRNAs accurately differentiates malignant from benign indeterminate thyroid lesions on fine needle aspiration. Clin Cancer Res 2012;18:2032-2038.
34. Shen R, Liyanarachchi S, Li W et al. MicroRNA signature in thyroid fine needle aspiration cytology applied to “atypia of undetermined significance” cases. Thyroid 2012;22:9-16.
35. Agretti P, Ferrarini E, Rago T et al. MicroRNA expression profile helps to distinguish benign nodules from papillarythyroid carcinomas starting from cells of fine-needle aspiration. Eur J Endocrinol 2012;167:393-400.
36. Lodewijk L, Prins AM, Kist JW et al. The value of miRNA in diagnosing thyroid cancer: A systematic review. Cancer Biomark 2012;11:229-238.
37. Kim S-J, Lee KE, Myong JP et al. BRAF V600E mutation is associated with tumor aggressiveness in papillary thyroid cancer. World J Surg 2012;36: 310-317.
38. Nam JK, Jung CK, Song BJ et al. Is the BRAF (V600E) mutation useful as a predictor of preoperative risk in papillary thyroid cancer? Am J Surg 2012;203:436-441.
39. Cheng S, Serra S, Mercado M et al. A high-throughput proteomic approach provides distinct signatures for thyroid cancer behavior. Clin Cancer Res 2011;17:2385-2394.
40. Khoo MLC, Freeman JL, Witterick IJ et al. Underexpression of p27/Kip in thyroid papillary microcarcinomas with gross metastatic disease. Arch Otolaryngol Head Neck Surg 2002;128:253-257.
41. Gao Y, Wang C, Shan Z et al. miRNA expression in a human papillary thyroid carcinoma cell line varies with invasiveness. Endocr J 2010;57:81-86.
42. Chou C-K, Chen R-F, Chou F-F. et al. miR-146bis highly expressed in adult papillarythyroid carcinomas with high risk features including extrathyroidal invasion and the BRAF(V600E) mutation. Thyroid 2010;20:489-494.
43. Chou C-K, Yang KD, Chou F-F et al. Prognostic implications of miR-146b expression and its functional role in papillary thyroid carcinoma. J Clin Endocrinol Metab 2013;98:E196-E205.
44. Lee JC, Zhao JT, Clifton-Bligh RJ et al. MicroRNA-222 and microRNA-146b are tissue and circulating biomarkers of recurrent papillary thyroid cancer. Cancer 2013;119:4358-4365.
45. Zhou Y-L, Liu C, Dai X-X. et al. Overexpression of miR-221 is associated with aggressive clinicopath-ologic characteristics and the BRAF mutation in papillarythyroid carcinomas. Med Oncol 2012;29: 3360-3366.
46. Nair VS, Maeda LS, Ioannidis JPA. Clinical outcome prediction by microRNAs in human cancer: A systematic review. J Natl Cancer Inst 2012;104: 528-540.
47. Schlumberger M, Sherman SI. Approach to the patient with advanced differentiated thyroid cancer. Eur J Endocrinol 2012;166:5-11.
48. Baudin E, Schlumberger M. New therapeutic approaches for metastatic thyroid carcinoma. Lancet Oncol 2007;8:148-156.
49. Nana-Sinkam SP, Croce CM. MicroRNA dysre-gulation in cancer: Opportunities for the development of microRNA-based drugs. IDrugs 2010;13: 843-846.
50. Bouchie A. First microRNA mimic enters clinic. Nat Biotechnol 2013;31:577.
51. Lin X, Guan H, Li H et al. miR-101 inhibits cell proliferation by targeting Rac1 in papillary thyroid carcinoma. Biomed Rep 2014;2:122-126.
52. Yu S, Liu Y, Wang J et al. Circulating microRNA profiles as potential biomarkers for diagnosis of papillarythyroid carcinoma. J Clin Endocrinol Metab 2012;97:2084-2092.